The Bonnie J. Addario Lung Cancer Foundation
The Lung Cancer Foundation's

LungBlog

An up-to-the-minute dose of health and hope for lung cancer

Bonnie Addario in UCSF Lab
 

Archive for the 'Small-Cell' Category

VePesid®/Platinol® Remains Standard-of-care for Small Cell Lung Cancer

MesotheliomaFor patients diagnosed with extensive-stage small-cell lung cancer (SCLC), the standard-of-care remains the chemotherapy combination of VePesid® (etoposide) and Platinol® (cisplatin). A recent study indicates that Camptosar® (irinotecan) plus Platinol does not improve survival in SCLC compared with VePesid/Platinol. These findings were presented at the 2008 annual meeting of the American Society of Clinical Oncology.

 

No Comments | Trackback | Permalink

 

Topotecan Approved in Europe for Treatment of Relapsed Small-Cell Lung Cancer

topocecan.jpgOral topotecan (Hycamtin) hard capsules have been approved by the European Commission for the treatment of relapsed small-cell lung cancer (SCLC). Specifically, topotecan hard capsules are indicated as monotherapy for the treatment of adult patients with relapsed SCLC (PS 0-2) for whom retreatment with the first-line regimen is not considered appropriate.

 

No Comments | Trackback | Permalink

 

Wellcome Trust Sanger Institute and Applied Biosystems Ally on Cancer Genetic Research

images1.jpgScientists will use five SOLiD™ Systems from Applied Biosystems to sequence the genome of a small cell lung cancer cell line and a noncancerous cell line.  Scientists from Sanger and Applied Biosystems plan to increase sequence coverage of both genomes by identifying one SNP for every 500,000 bases of DNA. One of the goals of this research is to generate 20-fold genome coverage of the cancer genome as well as the normal DNA using paired-end reads of a wide range of insert sizes.

 

No Comments | Trackback | Permalink

 

PhytoMedical Expands Scope of Patented Technology That Kills Cancer Cells

xray.jpgIn response to the success of the studies, PhytoMedicals collaborating scientists are now synthesizing and testing new derivatives of these anti-cancer agents. Further tests of the DNA binding anti-cancer agents are planned for human cancer cell lines specific to glioblastoma (tumors related to the brain) and small cell lung cancer, both of which are associated with a high mortality rate.

 

No Comments | Trackback | Permalink

 

Cancer Patient in Remission Three Years after Stem Cell Implant of Immune Response

gsk.jpgThe MAGE-A3 vaccine used in this study is manufactured by Glaxo-Smith-Kline, and is currently showing promise in Phase III trials in small cell lung cancer, the researchers said.

 

No Comments | Trackback | Permalink

 

Cancer survivor keeps breathing

PET.Ct.jpgTeresa Schumacher is “one in a million.”

Schumacher, 53, was diagnosed with small cell lung cancer in June 2005. Although survival rates for SCLC are low, she has beaten the odds after undergoing chemotherapy and the cancer has not returned.

 

No Comments | Trackback | Permalink

 

Avastin® Added Safely to Paraplatin® and Camptosar® for Small Cell Lung Cancer

avastin.jpgAccording to the results of a study presented at the 12th World Conference on Lung Cancer, the targeted therapy Avastin® (bevacizumab) can be safely added to chemotherapy with Paraplatin® (carboplatin) and Camptosar® (irinotecan) in patients with extensive-stage small cell lung cancer.

Lung cancer is the leading cause of cancer-related deaths in the United States and Europe. The two main types of lung cancer are small cell lung cancer (SCLC) and non–small cell lung cancer. Small cell lung cancer is less common than non-small cell lung cancer.

 

No Comments | Trackback | Permalink

 

Virus Shows Some Cancer-Killing Abilities

virus.jpgReporting in the Nov. 7 issue of Journal of the National Cancer Institute, researchers explained that the virus, Seneca Valley Virus-001 (SVV-001), was effective in treating lines of cells from small-cell lung cancer and some pediatric cancers, as well as lung cancer and eye cancer in immune-deficient mice.

 

No Comments | Trackback | Permalink

 

Thalomid® May not Improve Outcomes of Patients with Small-Cell Lung Cancer (SCLC)

thalomid.jpgResearchers from the UK have reported that the addition of Thalomid to etoposide plus Paraplatin (carboplatin) did not improve outcomes of patients with advanced small cell lung cancer SCLC). The details of this randomized trial were presented at the Presidential Symposium of the 12th World Conference on Lung Cancer in Seoul, Korea, September 2-6, 2007.

 

No Comments | Trackback | Permalink

 

Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer

clinical trial.jpgPharmion Corporation today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company’s third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

 

No Comments | Trackback | Permalink